Articles
Page 31 of 34
-
Citation: Alzheimer's Research & Therapy 2013 5:26
-
Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease
Despite the extensive mechanistic and pathological characterization of the amyloid precursor protein (APP)/presenilin-1 (PS-1) knock-in mouse model of Alzheimer's disease (AD), very little is known about the A...
Citation: Alzheimer's Research & Therapy 2013 5:28 -
Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease
Genetic studies have provided the best evidence for cause and effect relationships in Alzheimer's disease (AD). Indeed, the identification of deterministic mutations in the APP, PSEN1 and PSEN2 genes and subseque...
Citation: Alzheimer's Research & Therapy 2013 5:24 -
Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease
Addressing causes of heterogeneity in cognitive outcomes is becoming more critical as Alzheimer's disease (AD) research focuses on earlier disease. One of the causes of this heterogeneity may be that individua...
Citation: Alzheimer's Research & Therapy 2013 5:22 -
The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice
Despite years of research, there are no disease-modifying drugs for Alzheimer's disease (AD), a fatal, age-related neurodegenerative disorder. Screening for potential therapeutics in rodent models of AD has ge...
Citation: Alzheimer's Research & Therapy 2013 5:25 -
Advances in blood-based protein biomarkers for Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disorder that accounts for the majority of dementia cases. While research over the past decades has made advances into understanding disease pathology, definite ...
Citation: Alzheimer's Research & Therapy 2013 5:18 -
Modeling Alzheimer's disease with non-transgenic rat models
Alzheimer's disease (AD), for which there is no cure, is the most common form of dementia in the elderly. Despite tremendous efforts by the scientific community, the AD drug development pipeline remains extrem...
Citation: Alzheimer's Research & Therapy 2013 5:17 -
Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease
The Alzheimer's disease (AD) epidemic is a looming crisis, with an urgent need for new therapies to delay or prevent symptom onset and progression. There is growing awareness that clinical trials must target s...
Citation: Alzheimer's Research & Therapy 2013 5:21 -
5-HT6 receptors and Alzheimer's disease
During the past 20 years, the 5-HT6 receptor has received increasing attention and become a promising target for improving cognition. Several studies with structurally different compounds have shown that not only...
Citation: Alzheimer's Research & Therapy 2013 5:15 -
Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model
Type 2 diabetes mellitus has been identified as a risk factor for Alzheimer's disease (AD). An impairment of insulin signaling as well as a desensitization of its receptor has been found in AD brains. Glucose-...
Citation: Alzheimer's Research & Therapy 2013 5:20 -
Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models
Modulation of the gamma-secretase enzyme, which reduces the production of the amyloidogenic Aβ42 peptide while sparing the production of other Aβ species, is a promising therapeutic approach for the treatment of ...
Citation: Alzheimer's Research & Therapy 2013 5:19 -
DNA-dependent protein kinase and DNA repair: relevance to Alzheimer's disease
The pathological hallmark of Alzheimer's disease (AD), the leading cause of senile dementia, involves region-specific neuronal death and an accumulation of neuronal and extracellular lesions termed neurofibril...
Citation: Alzheimer's Research & Therapy 2013 5:13 -
The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection
Curcuminoids may improve pathological conditions associated with Alzheimer's disease. However, their therapeutic potential is limited by their exceedingly low bioavailability after oral administration. A metho...
Citation: Alzheimer's Research & Therapy 2013 5:16 -
Plasma tau levels in Alzheimer's disease
Citation: Alzheimer's Research & Therapy 2013 5:9 -
Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?
Alzheimer's disease (AD) pathophysiology is mostly (>95%) not inherited in a Mendelian fashion. Such sporadic AD (sAD) forms do not exhibit familial aggregation and are characterized by complex genetic inherit...
Citation: Alzheimer's Research & Therapy 2013 5:11 -
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Cerebrospinal fluid and positron emission tomography biomarkers accurately predict an underlying Alzheimer's disease (AD) pathology; however, they represent either invasive or expensive diagnostic tools. There...
Citation: Alzheimer's Research & Therapy 2013 5:8 -
Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems
Substances produced throughout the body are detectable in the blood, which is the most common biological fluid used in clinical testing. Biomarkers for Alzheimer's disease (AD) have long been sought in the blo...
Citation: Alzheimer's Research & Therapy 2013 5:10 -
Modeling the heterogeneity in risk of progression to Alzheimer's disease acrosscognitive profiles in mild cognitive impairment
Heterogeneity in risk of conversion to Alzheimer's disease (AD) among individualswith mild cognitive impairment (MCI) is well known. Novel statistical methods thatare based on partially ordered set (poset) mod...
Citation: Alzheimer's Research & Therapy 2013 5:14 -
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer's disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose with ...
Citation: Alzheimer's Research & Therapy 2013 5:12 -
The C9ORF72 mutation brings more answers and more questions
The clinical, neuropsychiatric and neuroimaging features of patients who carry the important new C9ORF72 mutation are discussed in this special series of Alzheimer's Research & Therapy. First reported in November...
Citation: Alzheimer's Research & Therapy 2013 5:7 -
Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery
The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alz...
Citation: Alzheimer's Research & Therapy 2013 5:5 -
Alcohol-related dementia: an update of the evidence
The characteristics of dementia relating to excessive alcohol use have received increased research interest in recent times. In this paper, the neuropathology, nosology, epidemiology, clinical features, and ne...
Citation: Alzheimer's Research & Therapy 2013 5:3 -
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine...
Citation: Alzheimer's Research & Therapy 2013 5:6 -
18F-florbetaben Aβ imaging in mild cognitive impairment
18F-florbetaben and positron emission tomography were used to examine the relationships between β-amyloid (Aβ) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive impai....
Citation: Alzheimer's Research & Therapy 2013 5:4 -
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
With increasing knowledge of clinical in vivo biomarkers and the pathological intricacies of Alzheimer's disease (AD), nosology is evolving. Harmonized consensus criteria that emphasize prototypic illness continu...
Citation: Alzheimer's Research & Therapy 2013 5:1 -
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Patients with Alzheimer's disease (AD) are currently treated with cholinesterase inhibitors, such as galantamine, without actual knowledge of its concentration in plasma. Our objective was to analyse potential...
Citation: Alzheimer's Research & Therapy 2013 5:2 -
Assessment of psychiatric changes in C9ORF72 frontotemporal dementia
Recent neuroimaging evidence highlights cerebellar atrophy as one feature of frontotemporal dementia (FTD) with C9ORF72 mutation. Interestingly, C9ORF72 patients do not present with classic cerebellar symptoms...
Citation: Alzheimer's Research & Therapy 2012 4:49 -
Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?
Parkinson's disease, the most common movement disorder, results in an insidious reduction for patients in quality of life and ability to function. A hallmark of Parkinson's disease is the brain accumulation of...
Citation: Alzheimer's Research & Therapy 2012 4:48 -
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulating enzyme with pro-inflammatory and oxidative activities associated with cardiovascular disease and ischemic stroke. While high plasma Lp-PLA2 activ...
Citation: Alzheimer's Research & Therapy 2012 4:51 -
NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease
Abundant neurochemical, neuropathological, and genetic evidence suggests that a critical number of proinflammatory and innate immune system-associated factors are involved in the underlying pathological pathwa...
Citation: Alzheimer's Research & Therapy 2012 4:47 -
Treatment implications of C9ORF72
Frontotemporal dementia (FTD) is a common dementia syndrome in patients under the age of 65 years with many features overlapping with amyotrophic lateral sclerosis (ALS). The link between FTD and ALS has been ...
Citation: Alzheimer's Research & Therapy 2012 4:46 -
Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
A substantial number of therapeutic drugs for Alzheimer's disease (AD) have failed in late-stage trials, highlighting the translational disconnect with pathology-based animal models.
Citation: Alzheimer's Research & Therapy 2012 4:50 -
Neuroimaging features of C9ORF72 expansion
Hexanucleotide expansion intronic to chromosome 9 open reading frame 72 (C9ORF72) has recently been identified as the most common genetic cause of both familial and sporadic amyotrophic lateral sclerosis and of f...
Citation: Alzheimer's Research & Therapy 2012 4:45 -
Stem cell models of Alzheimer's disease and related neurological disorders
Human models of Alzheimer's disease (AD) have the potential to complement existing animal models for carrying out functional studies of AD pathogenesis and the development of novel therapies. An effective huma...
Citation: Alzheimer's Research & Therapy 2012 4:44 -
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It...
Citation: Alzheimer's Research & Therapy 2012 4:43 -
Potential sources of interference on Abeta immunoassays in biological samples
Therapeutic products that depend on the use of an in vitro diagnostic biomarker test to confirm their effectiveness are increasingly being developed. Use of biomarkers is particularly meaningful in the context of...
Citation: Alzheimer's Research & Therapy 2012 4:39 -
Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease
Earlier reports of chromosome 9p-linked frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS) kindreds observed psychosis as a prominent feature in some patients. Since the discovery of chromo...
Citation: Alzheimer's Research & Therapy 2012 4:38 -
C9orf72 immunohistochemistry in Alzheimer's disease
Mutation in chromosome 9 open reading frame 72 (C9orf72) is a major genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), referred to as C9FTD/ALS. The function of the protein is...
Citation: Alzheimer's Research & Therapy 2012 4:37 -
Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions
Frontotemporal dementia (FTD) is a common cause of early-onset dementia with a significant genetic component, as underlined by the recent identification of repeat expansions in the gene C9ORF72 as a major cause o...
Citation: Alzheimer's Research & Therapy 2012 4:41 -
Dementia: a global health priority - highlights from an ADI and World Health Organization report
Alzheimer's Disease International is the worldwide federation of Alzheimer associations that represent people with dementia and their families. Alzheimer's Disease International has commissioned a number of Wo...
Citation: Alzheimer's Research & Therapy 2012 4:40 -
Championing of dementia in England
Dementia is starting to attract attention following decades of comparative neglect relative to other disease areas. England has been at the forefront of this sea change as one of the first countries in the wor...
Citation: Alzheimer's Research & Therapy 2012 4:36 -
Alzheimer's disease diagnostic criteria: practical applications
Alzheimer's disease (AD) can be identified prior to the occurrence of dementia by using biomarkers. Three phases of AD are recognized: an asymptomatic biomarker-positive phase, a phase with positive biomarkers...
Citation: Alzheimer's Research & Therapy 2012 4:35 -
Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterised by extracellular amyloid-ß (Aß) and intraneuronal tau protein brain pathologies. The most significant risk factor for non-famil...
Citation: Alzheimer's Research & Therapy 2012 4:32 -
Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort
Some familial Alzheimer's disease (AD) cases are caused by rare and highly-penetrant mutations in APP, PSEN1, and PSEN2. Mutations in GRN and MAPT, two genes associated with frontotemporal dementia (FTD), have be...
Citation: Alzheimer's Research & Therapy 2012 4:34 -
Dystrophic neurites express C9orf72 in Alzheimer's disease brains
Chromosome 9 open reading frame 72 (C9orf72) is an evolutionarily conserved protein with unknown function, expressed at high levels in the brain. An expanded hexanucleotide GGGGCC repeat located in the first i...
Citation: Alzheimer's Research & Therapy 2012 4:33 -
Impaired self-other differentiation in frontotemporal dementia due to the C9ORF72 expansion
An expanded hexanucleotide repeat in the C9ORF72 gene has recently been identified as an important cause of frontotemporal dementia and motor neuron disease; however, the phenotypic spectrum of this entity and it...
Citation: Alzheimer's Research & Therapy 2012 4:42 -
Con: Alzheimer's disease and circadian dysfunction: chicken or egg?
The development of late-onset Alzheimer's disease is believed to be influenced by genetic, socioeconomic, and lifestyle factors. Recently, converging research in animal and human studies has found that beta-am...
Citation: Alzheimer's Research & Therapy 2012 4:26 -
Pro: Alzheimer's disease and circadian dysfunction: chicken or egg?
Alzheimer's disease (AD) is a neurodegenerative disease that accounts for most cases of dementia. Besides progressive cognitive decline, circadian dysfunction is a prominent feature of AD. Circadian disruption...
Citation: Alzheimer's Research & Therapy 2012 4:25 -
Increased expression of the homologue of enhancer-of-split 1 protects neurons from beta amyloid neurotoxicity and hints at an alternative role for transforming growth factor beta1 as a neuroprotector
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of β-amyloid (Aβ) in the brain, which produces progressive neuronal loss and dementia. We recently demonstrated that the...
Citation: Alzheimer's Research & Therapy 2012 4:31 -
Expanding the genetics of amyotrophic lateral sclerosis and frontotemporal dementia
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized clinically by rapidly progressive paralysis leading ultimately to death from respiratory failure. It is now recognized tha...
Citation: Alzheimer's Research & Therapy 2012 4:30
Follow
- ISSN: 1758-9193 (electronic)